AstraZeneca
Company ● Covered in 3 stories + Follow ✴ AI Graph
This profile is built automatically from TLDRocket coverage.
Signals
2 stories (new)
Media momentum
As of 27 Oct 2026 · Visible stories in the last 30 days, compared with the 30 days before.
3 sources
Source diversity
As of 27 Oct 2026 · Distinct publications behind this entity's visible coverage.
—
Release activity
As of 27 Oct 2026 · Model, product and open-source release events in the last 90 days whose coverage involves this entity.
—
Funding signals
As of 27 Oct 2026 · Funding and acquisition events in the last 90 days whose coverage involves this entity.
Jul 2026 → Oct 2026
Coverage span
As of 27 Oct 2026 · First to most recent month of TLDRocket coverage of this entity.
Management
updated 5 Aug 2026- Pascal Soriot CEO
- Susan Galbraith EVP, Oncology R&D
- Ruud Dobber EVP & President, BioPharmaceuticals Business
- Pam Cheng EVP, Operations & IT
- Aradhana Sarin CFO
- Jeff Pott Chief Human Resources Officer, Chief Compliance Officer and General Counsel
- David Fredrickson EVP, Global Head Oncology Business Unit
- Anthony M. Senior Vice President, Head Of Quality (cqo)
- Leo E. Executive Director & General Manager
- Renee Iacona Chief Operating Officer - Oncology R&D
- Shamus Whyte Executive Director & General Manager
- Mohamed Gamal AstraZeneca CFO
+ 28 more tracked
Latest developments
Q4 2026
AstraZeneca invests in Pathos AI Funding
AstraZeneca and insitro announce a partnership Partnership
- AI drug development startup Pathos AI closes $237M investment
- AstraZeneca signs an AI drug discovery deal worth up to $1.5 billion
Q3 2026
Relationships
Partnerships
- Partnered with insitro · 1 source
Investment & ownership
- Invests in Pathos AI · 1 source
Products & technology
- insitro deploys this company · 1 source